Keeler Thomas Management LLC Takes Position in Halozyme Therapeutics, Inc. $HALO

Keeler Thomas Management LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 18,905 shares of the biopharmaceutical company’s stock, valued at approximately $983,000.

Several other institutional investors also recently modified their holdings of HALO. Caisse DE Depot ET Placement DU Quebec grew its holdings in shares of Halozyme Therapeutics by 154.5% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 910,169 shares of the biopharmaceutical company’s stock valued at $58,078,000 after acquiring an additional 552,590 shares in the last quarter. LSV Asset Management grew its holdings in Halozyme Therapeutics by 41.9% during the first quarter. LSV Asset Management now owns 895,191 shares of the biopharmaceutical company’s stock valued at $57,122,000 after purchasing an additional 264,130 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in Halozyme Therapeutics by 27.3% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock valued at $72,107,000 after purchasing an additional 242,167 shares during the period. MetLife Investment Management LLC grew its holdings in Halozyme Therapeutics by 136.6% during the first quarter. MetLife Investment Management LLC now owns 343,741 shares of the biopharmaceutical company’s stock valued at $21,934,000 after purchasing an additional 198,476 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new position in Halozyme Therapeutics during the first quarter valued at $11,636,000. 97.79% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on HALO. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. Zacks Research cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Hold” and an average price target of $72.89.

Halozyme Therapeutics Trading Down 1.1%

Shares of HALO stock opened at $66.15 on Friday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $79.50. The company has a market capitalization of $7.74 billion, a PE ratio of 15.14, a price-to-earnings-growth ratio of 0.36 and a beta of 1.16. The business’s fifty day moving average is $71.71 and its 200 day moving average is $62.31.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same quarter last year, the business posted $0.91 earnings per share. The firm’s revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $69.03, for a total value of $1,380,600.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $50,648,622.57. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Nicole Labrosse sold 2,227 shares of Halozyme Therapeutics stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the transaction, the chief financial officer owned 22,079 shares in the company, valued at approximately $1,721,058.05. This represents a 9.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 108,227 shares of company stock worth $7,779,595 over the last 90 days. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.